Please login to the form below

Not currently logged in

AZ donates Brixham lab to Plymouth University

Will create global research and education facility

AstraZeneca AZ Brixham Lab DevonAstraZeneca (AZ) has negotiated a deal that will keep its environmental laboratory in Brixham, UK, in operation, although it will not rescue the jobs of those currently working there.

The pharma company will donate the Brixham facility and all its equipment to Plymouth University, which will use the site to create a "global research and education facility" focusing on marine and environmental research.

AZ took the decision to close down the unit in south Devon in October and contract out all the work currently carried out there, resulting in the loss of 71 jobs. The Brixham facility provided specialist services to assess the environmental impact of pharmaceuticals and chemicals, working both for other AZ divisions as well as other companies.

In addition to serving as a working lab Plymouth University expects to use the facility for technology transfer activities, tapping into Growth Acceleration and Investment Network (GAIN) set up by the University, Plymouth City Council and Tamar Science Park.

"Our aim has been to ensure the laboratory and its state of the art facilities remain in use for scientific purposes," commented Steve Rumford, head of the environment team at AZ, although the company confirmed that the agreement does not include the transfer of AZ staff or third-party work commitments.

"Plymouth University is a world-class teaching and research institution and we are confident that we have chosen the right partner to secure a successful future for the site," he added.

Local MP Dr Sarah Wollaston welcomed the decision but said she was still "saddened" by AZ's decision to pull out of the area.

"I would like to thank them for understanding the importance of science to this area; a responsible exit will allow the creation of highly skilled jobs and an international centre of excellence," she added.

AZ staff have faced a dramatic 12 months as the company announced plans to reduce its headcount by around 4,000, downsize its UK research operations and leave its Alderley Park facility in Cheshire for a new site in Cambridge.

The company said its priority is to ensure its employees are fully supported over the coming weeks and months, as it progresses its "responsible exit plans."

Article by
Phil Taylor

10th December 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...